Everolimus attenuates glutamate-induced PC12 cells death.
Alavi MS, Fanoudi S, Hosseini A, Jalili-Nik M, Bagheri A, Sadeghnia HR.
Int J Neurosci · journal article · DOI 10.1080/00207454.2021.1929210 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för everolimus. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
19 hitsEverolimus-Eluting Stent-induced Pneumonitis.
Kobayashi H.
Am J Respir Crit Care Med · journal article · DOI 10.1164/rccm.202103-0565imAntitumor activity of everolimus in recurrent metastatic endometrial cancer with <i>PTEN</i> deletion: a case report.
Zhang X, Shi J, Li J, Shi X, Liu X, Zhang Y, Cui Y.
Gland Surg · journal article; case reports; case-report · DOI 10.21037/gs-21-422Liposomes Loaded with Everolimus and Coated with Hyaluronic Acid: A Promising Approach for Lung Fibrosis.
Pandolfi L, Marengo A, Japiassu KB, Frangipane V, Tsapis N, Bincoletto V, Codullo V, Bozzini S, Morosini M, Lettieri S, Vertui V, Piloni D, Arpicco S, Fattal E, Meloni F.
Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms22147743Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma.
Lee CH, Wan Y, Smith A, Xie R, Motzer RJ.
Eur Urol Open Sci · research-article; journal article · DOI 10.1016/j.euros.2021.06.008PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Mpilla GB, Uddin MH, Al-Hallak MN, Aboukameel A, Li Y, Kim SH, Beydoun R, Dyson G, Baloglu E, Senapedis WT, Landesman Y, Wagner KU, Viola NT, El-Rayes BF, Philip PA, Mohammad RM, Azmi AS.
Mol Cancer Ther · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1535-7163.mct-20-1105Dosing-time dependent testicular toxicity of everolimus in mice.
Ozturk N, Ozturk Civelek D, Sancar S, Kaptan E, Pala Kara Z, Okyar A.
Eur J Pharm Sci · journal article · DOI 10.1016/j.ejps.2021.105926Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.
Guarneri V, Giorgi CA, Cinieri S, Bengala C, Mariani G, Bisagni G, Frassoldati A, Zamagni C, De Rossi C, Amoroso V, Andreetta C, Ferro A, Zambelli A, Gori S, Garrone O, Dieci MV, Orlando L, Pastina I, Beninato T, Moretti G, Genovesi E, Cinefra M, Vicini R, Magni G, De Salvo GL, Conte P.
Eur J Cancer · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.ejca.2021.05.008A pilot study of everolimus and radiation for neuroendocrine liver metastases.
Myrehaug S, Chan DL, Rodriguez-Freixinos V, Chung H, Hallet J, Law C, Patel C, Milot L, Hudson J, Chen H, Singh S.
Endocr Relat Cancer · research support, non-u.s. gov't; journal article · DOI 10.1530/erc-21-0030Did Everolimus Break the Rules?
Kato S, Cohen EEW.
Clin Cancer Res · comment; journal article · DOI 10.1158/1078-0432.ccr-21-1508Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors.
Raj N, Zheng Y, Hauser H, Chou J, Rafailov J, Bou-Ayache J, Sawan P, Chaft J, Chan J, Perez K, Rudin C, Tang L, Reidy-Lagunes D.
Endocr Relat Cancer · research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1530/erc-20-0446Four-Year Outcomes of Multivessel Percutaneous Coronary Intervention With Xience V Everolimus-Eluting Stents.
Lee MS, Shlofmitz R, Mahmud E, Park KW, Rha SW, Gaborro A, Wang J, Zhao W, Sudhir K.
J Invasive Cardiol · journal article · DOI 10.25270/jic/19.3109.240A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor.
Gurk-Turner C, Manitpisitkul W, Cooper M.
Transplantation · review; journal article · DOI 10.1097/tp.0b013e31825b411cEverolimus-induced pneumonitis after drug-eluting stent implantation: a case report.
Sakamoto S, Kikuchi N, Ichikawa A, Sano G, Satoh K, Sugino K, Isobe K, Takai Y, Shibuya K, Homma S.
Cardiovasc Intervent Radiol · journal article; case reports · DOI 10.1007/s00270-012-0477-ymTOR inhibitors in breast cancer: a systematic review.
Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R.
Gynecol Oncol · research support, non-u.s. gov't; systematic review; journal article · DOI 10.1016/j.ygyno.2012.08.040Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
Nashan B, Gaston R, Emery V, Säemann MD, Mueller NJ, Couzi L, Dantal J, Shihab F, Mulgaonkar S, Seun Kim Y, Brennan DC.
Transplantation · research support, non-u.s. gov't; review; journal article · DOI 10.1097/tp.0b013e31824810e6Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
Barnett CM.
Pharmacotherapy · research support, non-u.s. gov't; review; journal article · DOI 10.1002/j.1875-9114.2012.01084.xEverolimus: preventing organ rejection in adult kidney transplant recipients.
Dantal J.
Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2012.662955Novel protein kinase signaling systems regulating lifespan identified by small molecule library screening using Drosophila.
Spindler SR, Li R, Dhahbi JM, Yamakawa A, Sauer F.
PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0029782